GigaGen Inc is a biotechnology startup founded in 2010 and headquartered in the United States. It is a subsidiary of Grifols and is focused on developing groundbreaking antibody drugs for immune deficiency, infectious diseases, and checkpoint-resistant cancers.
The company's proprietary single-cell technologies enable the capture and recreation of complete immune repertoires as functional antibody libraries, leading to the creation of first-in-class recombinant polyclonal antibody therapies for infectious diseases. GigaGen's lead oncology asset, GIGA-564, is an anti-CTLA-4 monoclonal antibody that has demonstrated improved anti-tumor efficacy through a unique mechanism of action.
GigaGen's innovative approach and novel technology platforms position it at the forefront of drug discovery and development. The company continues to leverage its proprietary technologies for the discovery of novel recombinant polyclonal drugs and monoclonal antibodies to address life-threatening diseases.
The company received a private equity investment on 07 July 2017, showcasing investor confidence in its potential to make a significant impact in the biotechnology and health and wellness industries.
| Funding Stage | Amount | No. Investors | Investors | Date |
|---|---|---|---|---|
| Private Equity | Unknown | - | 07 Jul 2017 | |
| Grant | Unknown | - | 05 Mar 2015 | |
| Grant | Unknown | - | 06 Sep 2014 | |
| Grant | Unknown | - | 13 Jul 2014 | |
| Grant | Unknown | - | 15 Sep 2013 |
No recent news or press coverage available for GigaGen Inc.
We care about your data, and we'd love to use cookies make your experience better.
